Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Small Cell Lung Carcinoma 2Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Neurofibrosarcoma 1Neuroblastoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cytarabine 167fludarabine phosphate 102Cyclophosphamide 97Azacitidine 92Whole-Body Irradiation 78fludarabine 77Mycophenolic Acid 71Busulfan 68Tacrolimus 59Peripheral Blood Stem Cell Transplantation 55Decitabine 55Granulocyte Colony-Stimulating Factor 49Filgrastim 44Daunorubicin 44Cyclosporine 42Methotrexate 41Melphalan 41Etoposide 41Clofarabine 41Idarubicin 39Mitoxantrone 34Antilymphocyte Serum 34venetoclax 32thymoglobulin 23Thiotepa 23Stem Cell Transplantation 21Injections 16Gemtuzumab 16CPX-351 16Sirolimus 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myeloid, Acute × lorvotuzumab mertansine × Clear all
NCT02420873 2018-08-28

An Open-label Phase II Study of Lorvotuzumab Mertansine

M.D. Anderson Cancer Center

Phase 2 Completed
9 enrolled 7 charts
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡